Pfizer Inc. (PFE)
| Market Cap | 133.72B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 17.00 |
| Forward PE | 8.32 |
| Dividend | $1.72 (7.31%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 57,044,439 |
| Open | 23.17 |
| Previous Close | 23.00 |
| Day's Range | 23.16 - 23.70 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 29.92 (+27.21%) |
| Earnings Date | Apr 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 27.21% from the latest price.
News
Pfizer Pacing for 4th Day of Gains
Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains.
Pfizer Thinks Bigger With 3SBio Deal
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows inc...
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Pfizer strikes deal with China's 3SBio to license cancer drug
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.
Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug
Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing tr...
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutic...
Buy These 2 Beaten Down Stocks Now Before They Rally
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headw...
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Nao...
Pfizer's Turnaround Story Is Stronger Than You Think
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasan...
2 Game-Changing Additions To Your Retirement Income Portfolio
Retirement income investing should prioritize risk management, income stability, and capital preservation over aggressive growth strategies. To achieve that, investors tend to allocate high-quality va...
US House panel seeks information from Pfizer over alleged COVID vaccine delay
U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 va...
New allegations about timing of Pfizer Covid vaccine passed to House panel
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen acquisiti...
Dividend Harvesting Portfolio Week 219: $21,900 Allocated, $2,206.52 In Projected Dividends
I'm bullish on the second half of 2025, expecting further market gains if CPI trends lower and trade talks progress positively. Despite a small portfolio decline this week, my Dividend Harvesting Port...
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors t...
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albe...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...